-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, an innovative drug for the control of blood sugar in type 2 diabetic patients-insulin deglulam and liraglutide injection (English common name: IDegLira; trade name: Novo benefit), won China Approved by the National Medical Products Administration (NMPA), it is suitable for adult type 2 diabetes patients with poor blood sugar control
.
It is combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control .
Related information shows that Novobio is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which can be injected at any time of the day (preferably at the same time every day).
And it has nothing to do with meal time
.
Its approval for listing in China is expected to bring new treatment options to Chinese patients with type 2 diabetes
.
Image source: 123RF disease affecting hundreds of millions of Chinese people.
Diabetes is a common systemic metabolic disease.
Due to problems in the regulation and utilization of sugar in the patient’s body, the glucose concentration in the blood increases, which can lead to various organs in the body.
Especially the long-term damage, insufficiency and failure of the eyes, kidneys, nerves and cardiovascular system are harmful to health and life
.
The harm of diabetes is not only the disease itself, but also a series of serious complications, such as diabetic ketoacidosis, hypertonic hyperglycemia, vascular complications, microvascular complications, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and Diabetic foot disease and so on
.
A blockbuster report on diabetes released by The Lancet showed that there were approximately 463 million diabetic patients worldwide in 2019; 4.
2 million people died of diabetes and its complications, accounting for 8.
4% of the global deaths; for 40 For people aged -60, having diabetes means an average reduction in life expectancy of 4-10 years
.
In China, a study published in the British Medical Journal in 2020 shows that the number of diabetes patients in China has exceeded 129.
8 million, of which more than 90% are type 2 diabetes patients
.
In addition, what is even more worrying is that only 49.
4% of the treated patients met the blood glucose target (glycated hemoglobin [HbA1c] <7%)
.
Image source: 123RF's world's first basal insulin GLP-1RA injection Novo benefit is composed of insulin deglulam and liraglutide, which combines the two-component advantages of insulin deglu and liraglutide
.
Insulin degludec is a new generation of super long-acting basal insulin analogue, which has the characteristics of stable, safe and effective blood sugar control
.
It is reported that the insulin glutathione used in Novo Yizhong can achieve an ultra-long-acting action time of 42 hours
.
Liraglutide, a GLP-1 analog that is injected once a day, is 97% similar to the naturally occurring human GLP-1
.
Like human GLP-1, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, and reduces body weight and body fat by increasing satiety and reducing energy intake
.
The two main components of insulin degludec and liraglutide work through complementary mechanisms to effectively control blood sugar throughout the day once a day.
The HbA1c compliance rate is as high as 89.
9%, which reduces the risk of hypoglycemia and has clear weight gains
.
Image source: 123RF effectively reduces HbA1cDUAL Ⅰ Chinese research shows that Novozymes can effectively reduce HbA1c
.
The DUAL Ⅰ study included a total of 720 cases of metformin combined with or without another oral hypoglycemic drug in the treatment of Chinese adult type 2 diabetes patients with poor blood sugar control.
Their HbA1c averaged 8.
2%
.
According to the ratio of 2:1:1, the participants were divided into 3 groups, and they were treated with Nuovo+Metformin, Glutamicin+Metformin, and Liraglutide+Metformin
.
After 26 weeks, the HbA1c of the participants in the Novo Benefit group dropped more, and 77% of the participants met the HbA1c standard; while the insulin deglubber group was 46.
4%, and the liraglutide group was 48.
3%
.
In addition, the Novozyme group had a low risk of hypoglycemia; compared with the insulin deglubber group, participants gained less weight and had fewer daily insulin doses
.
The DUAL Ⅱ Chinese study confirmed that compared with the control drug, Novozyme can achieve better blood sugar control.
More patients achieve HbA1c<7% without hypoglycemia and/or weight gain, and lower daily insulin dosage
.
Image source: 123RF We expect that with the launch of Novozymes in China, it will bring easy-to-control blood glucose management for patients, and help more Chinese patients with type 2 diabetes meet high-quality blood glucose standards
.
Recommended reading New Options for Diabetes Treatment! The new generation of insulin sensitizer "siglita sodium" was approved to be marketed for the treatment of malignant pleural mesothelioma, and dual immunotherapy was approved! The patient assistance project was launched simultaneously, China ushered in the second CAR-T product! Recommendations for the treatment of relapsed or refractory large B-cell lymphoma! For the treatment of classic Hodgkin’s lymphoma, another new anti-PD-1 antibody drug was approved to treat psoriasis, and oral targeted drugs were approved for marketing reference materials[1] EU approved the launch of Xultophy, a diabetes compound product[J].
World Clinic Drugs, 2014, 35(274), 10 91.
[2] [New Product Express: Insulin Deglulam/Liraglutide Injection] IDegLira China data hits big.
Retrieved Oct 28, 2021, from https://mp .
weixin.
qq.
com/s/VMlDNvpmj7TsE4emMjgKLA[3] [New product express: insulin deglulam/liraglutide injection] IDegLira China data is coming again.
Retrieved Oct 28, 2021, from https://mp.
weixin.
qq.
com/s/scnvrOCe03BhGsJRQiEJiw.
Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
It is combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control .
Related information shows that Novobio is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which can be injected at any time of the day (preferably at the same time every day).
And it has nothing to do with meal time
.
Its approval for listing in China is expected to bring new treatment options to Chinese patients with type 2 diabetes
.
Image source: 123RF disease affecting hundreds of millions of Chinese people.
Diabetes is a common systemic metabolic disease.
Due to problems in the regulation and utilization of sugar in the patient’s body, the glucose concentration in the blood increases, which can lead to various organs in the body.
Especially the long-term damage, insufficiency and failure of the eyes, kidneys, nerves and cardiovascular system are harmful to health and life
.
The harm of diabetes is not only the disease itself, but also a series of serious complications, such as diabetic ketoacidosis, hypertonic hyperglycemia, vascular complications, microvascular complications, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and Diabetic foot disease and so on
.
A blockbuster report on diabetes released by The Lancet showed that there were approximately 463 million diabetic patients worldwide in 2019; 4.
2 million people died of diabetes and its complications, accounting for 8.
4% of the global deaths; for 40 For people aged -60, having diabetes means an average reduction in life expectancy of 4-10 years
.
In China, a study published in the British Medical Journal in 2020 shows that the number of diabetes patients in China has exceeded 129.
8 million, of which more than 90% are type 2 diabetes patients
.
In addition, what is even more worrying is that only 49.
4% of the treated patients met the blood glucose target (glycated hemoglobin [HbA1c] <7%)
.
Image source: 123RF's world's first basal insulin GLP-1RA injection Novo benefit is composed of insulin deglulam and liraglutide, which combines the two-component advantages of insulin deglu and liraglutide
.
Insulin degludec is a new generation of super long-acting basal insulin analogue, which has the characteristics of stable, safe and effective blood sugar control
.
It is reported that the insulin glutathione used in Novo Yizhong can achieve an ultra-long-acting action time of 42 hours
.
Liraglutide, a GLP-1 analog that is injected once a day, is 97% similar to the naturally occurring human GLP-1
.
Like human GLP-1, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, and reduces body weight and body fat by increasing satiety and reducing energy intake
.
The two main components of insulin degludec and liraglutide work through complementary mechanisms to effectively control blood sugar throughout the day once a day.
The HbA1c compliance rate is as high as 89.
9%, which reduces the risk of hypoglycemia and has clear weight gains
.
Image source: 123RF effectively reduces HbA1cDUAL Ⅰ Chinese research shows that Novozymes can effectively reduce HbA1c
.
The DUAL Ⅰ study included a total of 720 cases of metformin combined with or without another oral hypoglycemic drug in the treatment of Chinese adult type 2 diabetes patients with poor blood sugar control.
Their HbA1c averaged 8.
2%
.
According to the ratio of 2:1:1, the participants were divided into 3 groups, and they were treated with Nuovo+Metformin, Glutamicin+Metformin, and Liraglutide+Metformin
.
After 26 weeks, the HbA1c of the participants in the Novo Benefit group dropped more, and 77% of the participants met the HbA1c standard; while the insulin deglubber group was 46.
4%, and the liraglutide group was 48.
3%
.
In addition, the Novozyme group had a low risk of hypoglycemia; compared with the insulin deglubber group, participants gained less weight and had fewer daily insulin doses
.
The DUAL Ⅱ Chinese study confirmed that compared with the control drug, Novozyme can achieve better blood sugar control.
More patients achieve HbA1c<7% without hypoglycemia and/or weight gain, and lower daily insulin dosage
.
Image source: 123RF We expect that with the launch of Novozymes in China, it will bring easy-to-control blood glucose management for patients, and help more Chinese patients with type 2 diabetes meet high-quality blood glucose standards
.
Recommended reading New Options for Diabetes Treatment! The new generation of insulin sensitizer "siglita sodium" was approved to be marketed for the treatment of malignant pleural mesothelioma, and dual immunotherapy was approved! The patient assistance project was launched simultaneously, China ushered in the second CAR-T product! Recommendations for the treatment of relapsed or refractory large B-cell lymphoma! For the treatment of classic Hodgkin’s lymphoma, another new anti-PD-1 antibody drug was approved to treat psoriasis, and oral targeted drugs were approved for marketing reference materials[1] EU approved the launch of Xultophy, a diabetes compound product[J].
World Clinic Drugs, 2014, 35(274), 10 91.
[2] [New Product Express: Insulin Deglulam/Liraglutide Injection] IDegLira China data hits big.
Retrieved Oct 28, 2021, from https://mp .
weixin.
qq.
com/s/VMlDNvpmj7TsE4emMjgKLA[3] [New product express: insulin deglulam/liraglutide injection] IDegLira China data is coming again.
Retrieved Oct 28, 2021, from https://mp.
weixin.
qq.
com/s/scnvrOCe03BhGsJRQiEJiw.
Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
